Foghorn’s $110M offering; Novovax investor withdraws proxy campaign

Plus, news about En­deav­or Bio­sciences, Vi­core, Ar­row­head and Apri­noia Ther­a­peu­tics:

Foghorn prices $110M of­fer­ing: The Cam­bridge, MA-based biotech priced the of­fer­ing at $5.51 per share $FHTX. It was trad­ing at about $5.65 apiece on Mon­day morn­ing. — Kyle LaHu­cik

No­vavax in­vestor with­draws proxy fight: Shah Cap­i­tal Man­age­ment, one of the largest share­hold­ers of No­vavax with about 8% own­er­ship, with­drew its proxy cam­paign against the re-elec­tion of di­rec­tors to the vac­cine mak­er’s board. Shah said it “still be­lieves No­vavax would ben­e­fit from [a] stock­hold­er rep­re­sen­ta­tive on board.” No­vavax dis­closed a vac­cine deal with Sanofi last week. — Kyle LaHu­cik

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.